69 related articles for article (PubMed ID: 23490034)
1. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy.
Alfaleh FZ; Alswat K; Helmy A; Al-hamoudi W; El-sharkawy M; Omar M; Shalaby A; Bedewi MA; Hadad Q; Ali SM; Alfaleh A; Abdo AA
Liver Int; 2013 Jul; 33(6):871-83. PubMed ID: 23490034
[TBL] [Abstract][Full Text] [Related]
2. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
[TBL] [Abstract][Full Text] [Related]
3. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
4. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
Saad Y; Ahmed A; Saleh DA; Doss W
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
[TBL] [Abstract][Full Text] [Related]
5. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
6. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
8. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
[TBL] [Abstract][Full Text] [Related]
9. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
10. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
[TBL] [Abstract][Full Text] [Related]
11. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
12. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
Bate JP; Colman AJ; Frost PJ; Shaw DR; Harley HA
J Gastroenterol Hepatol; 2010 Jul; 25(7):1276-80. PubMed ID: 20594255
[TBL] [Abstract][Full Text] [Related]
15. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
Baur K; Mertens JC; Schmitt J; Iwata R; Stieger B; Frei P; Seifert B; Bischoff Ferrari HA; von Eckardstein A; Müllhaupt B; Geier A;
Antivir Ther; 2012; 17(3):541-7. PubMed ID: 22300961
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
Ceylan B; Arslan F; Yardimci C; Fincanci M; Özgüneş N
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):493-4. PubMed ID: 24598385
[No Abstract] [Full Text] [Related]
17. Hepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in Belgium is similar to genotype 1.
de Galocsy C; Kaufman L; Tomasovic S; Delwaide J; Nevens F
Acta Gastroenterol Belg; 2010; 73(2):229-34. PubMed ID: 20690561
[TBL] [Abstract][Full Text] [Related]
18. Surgical Outcomes in Hepatitis C Virus-Related Hepatocellular Carcinoma: Special Reference to Sustained Virological Responses to Interferon Therapy.
Tanaka S; Tamori A; Takemura S; Hamano G; Ito T; Kawada N; Kubo S
Am Surg; 2017 Nov; 83(11):1246-1255. PubMed ID: 29183527
[TBL] [Abstract][Full Text] [Related]
19. Outcome of a hepatitis C outbreak among patients in a pain management clinic.
Fazili J; Mallonee S; Tierney WM; Bader TF; Sachdev AK; Bird PC; Schmidt RD; Mesiya SA; Lackey CL
Dig Dis Sci; 2010 Jun; 55(6):1738-43. PubMed ID: 20411419
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C genotype influences post-liver transplant outcomes.
Campos-Varela I; Lai JC; Verna EC; O'Leary JG; Todd Stravitz R; Forman LM; Trotter JF; Brown RS; Terrault NA;
Transplantation; 2015 Apr; 99(4):835-40. PubMed ID: 25211520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
